Inovio Pharmaceuticals, Inc. (INO) vs Sera Prognostics, Inc. (SERA)
A side-by-side comparison of Inovio Pharmaceuticals, Inc. and Sera Prognostics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INO
Inovio Pharmaceuticals, Inc.
$1.15HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
SERA
Sera Prognostics, Inc.
$2.02HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT
Total return — INO vs SERA
growth of $100 · dividends reinvested · last 5yINO -98.8% (-58.7%/yr)SERA -83.2% (-30.0%/yr)SERA compounded faster over this window
Log scale — wide-divergence pair
INO SERA
INO vs SERA: by the numbers
- •INO is the larger company ($79M vs $77M market cap).
- •Both run net losses; SERA's is the smaller (-47475.71% vs -130000.00% net margin).
Metrics side by side
Valuation
| Metric | INO | SERA |
|---|---|---|
| P/S ratio | N/A | 1102.08 |
| P/B ratio | 18.13 | 1.30 |
Profitability
| Metric | INO | SERA |
|---|---|---|
| Gross margin | 100.00% | -102.47% |
| Operating margin | -132871.32% | -45066.67% |
| Net margin | -130000.00% | -47475.71% |
| ROE | -1542.57% | -55.97% |
| ROIC | -836.58% | -59.79% |
Growth (annualized)
| Metric | INO | SERA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.73% |
| Total return CAGR (5Y) | -57.05% | -28.91% |
Frequently asked
- How have INO and SERA total returns compared?
- Over the past 5 years, INO delivered -57.05% and SERA delivered -28.91% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.